| Popis: |
Latest Standards of Medical Care in Diabetes was presented in January 2022. Among oral hypoglycemic agents (OHAs), imeglimin has been topic for a novel agent for type 2 diabetes mellitus (T2DM). Pharmacologically, imeglimin is a cyclic molecule including triazine ring. It has both pharmacological mechanism of increased insulin action and elevation of glucose-stimulated insulin secretion (GSIS). Clinically, it showed HbA1c reduction for 0.46% by monotherapy and 0.56-0.92% by combined therapy with other OHAs. From compared administration of 500mg, 1000mg and 1500mg, 1000mg twice doses would be adequate. No remarkable treatment-emergent adverse events (TEAEs) were found for treatment of imeglimin. |
